PMID: 620227Jan 21, 1978Paper

Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus

British Medical Journal
A MelanderP O Bitzén

Abstract

A selective and sensitive gas chromatographic technique was used to measure the steady-state serum concentrations of tolbutamide and chlorpropamide in 97 patients with maturity-onset diabetes mellitus who had been taking these drugs (37 tolbutamide, 60 chlorpropamide) for at least a year. No other antidiabetic agents had been given. The serum tolbutamide concentrations varied widely between the patients (from close to zero to 370 mumol/l (100 mug/ml)), yet the variation in dosage was only sixfold (0.5-3.9 g daily). The serum chlorpropamide concentrations varied even more widely (from close to zero to 882 mumol/l (244 mug/ml)), though the dosage variation was fourfold (125-500 mg daily). There was no systematic relation between dosage and serum concentrations of the drugs.Only 2 (5.4%) of the tolbutamide-treated patients and 10 (16.7%) of the chlorpropamide-treated patients had normal fasting blood glucose concentrations (below 5.5 mmol/l (99 mg/100 ml)), and fewer than half had values below 8.0 mmol/l (144 mg/100 ml). In most cases, therefore, the treatment was insufficient.There was no significant difference in mean fasting blood glucose concentrations between the two treatment groups. The mean steady-state concentration of ch...Continue Reading

References

Jan 1, 1976·Clinical Pharmacokinetics·G Johnsson, C G Regàrdh
Mar 3, 1977·The New England Journal of Medicine·S W Shen, R Bressler
Sep 1, 1972·The Journal of Pharmacy and Pharmacology·L F Prescott, D R Redman
Sep 20, 1972·Journal of Chromatography·D L SimmonsP Picotte

Citations

Jan 1, 1982·European Journal of Clinical Pharmacology·E J AntalK S Albert
Aug 1, 1980·European Journal of Clinical Pharmacology· Wilholm B-E
Aug 1, 1980·European Journal of Clinical Pharmacology·U BergmanJ Ostman
Jan 1, 1982·European Journal of Clinical Pharmacology·E Wåhlin-BollB Scherstén
Apr 1, 1980·European Journal of Clinical Pharmacology·G SartorE Wåhlin-Boll
Dec 10, 2003·Archives of Pharmacal Research·Jun Shik Choi, Sang Chul Shin
Mar 21, 2000·Diabetes Research and Clinical Practice·C D AgardhP Nilsson-Ehle
Oct 1, 1979·British Journal of Clinical Pharmacology·C G SwiftI H Stevenson
Jun 1, 1990·British Journal of Clinical Pharmacology·S W CoppackA V Rodgers
Jun 1, 1991·British Journal of Clinical Pharmacology·M A PageG M Shenfield
May 25, 2013·Science·Hirohito HarukiKai Johnsson
Aug 1, 1993·American Journal of Obstetrics and Gynecology·I W Smoak
Jan 1, 1988·The American Journal of Medicine·D C Klonoff
Jan 1, 1985·British Journal of Clinical Pharmacology·R J DowT E Isles
Feb 28, 2001·Diabetes, Obesity & Metabolism·U Lindblad, A Melander
Jan 1, 1983·Human Toxicology·J FeelyT E Isles
Jan 1, 1981·Acta Medica Scandinavica. Supplementum·A MelanderE Wåhlin-Boll

Related Concepts

Blood Glucose
Insogen
Chromatography, Gas-Liquid
Diabetes Mellitus
Tolbutamid R.A.N.

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Generating Insulin-Secreting Cells

Reprogramming cells or using induced pluripotent stem cells to generate insulin-secreting cells has significant therapeutic implications for diabetics. Here is the latest research on generation of insulin-secreting cells.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Epigenome Editing

Epigenome editing is the directed modification of epigenetic marks on chromatin at specified loci. This tool has many applications in research as well as in the clinic. Find the latest research on epigenome editing here.